This week's efficacy a treatment to address different types of cancer, prepared by Spanish researchers at Gregorio Marañón Hospital in Madrid, Navarra University Clinic and Ramón y Cajal Hospital.
According to a press release, preliminary clinical trials have shown that the BO-112 molecule has managed to control the disease in the disease 58% of cases and reduces the tumor by 17%. "It is an" intratumoral therapy with an immunomodulatory effect developed entirely in Spain".
For therapy, "anti-PD-1 / PD-L1 antibodies (immunotherapeutic drugs in tumors such as melanoma, lung and kidney, among others) "what" revolutionized the treatment and prognosis of cancer patients, "they added.
This research completed the first phase of the Phase I clinical trial after try 28 people. Their data were presented at the last European Congress of Medical Oncology, which took place in Munich, Germany.
Expanding the study
Beyond the promising results, Iván Márquez Rodas, an oncologist at Gregorio Marañón Hospital and co-director of the project, warned that "these should be considered as preliminary."
That's why, of the three medical institutions that have participated in a start, now tests will be extended to four other hospitals. "Our intention is to continue to advance our knowledge of the security profile, the BO-112 action mechanisms, and Find out if there is more efficacy and how long it lasts in patients who have not previously had anti-PD-1 treatment, "added Márquez Rodas.
In turn, Ignacio Melero, an immunologist at Navarra University Hospital and co-director of the project, explained the functioning of the treatment: "Philosophy is to try to turn some of the tumorous lesions into an immunogenic tissue that wakes up an immune response, helping immune response to the rest of the body. "Similarly, while this process takes place" systemically in the rest of the body, "mechanisms that slow the immune response are inhibited," he added.
If you liked it, share it with your friends!